To review (retrospectively) the relationships between lamotrigine (LTG) dosage and plasma concentrations based on data generated in a routine therapeutic drug monitoring laboratory from a heterogeneous sample of patients with epilepsy. To distinguish patients taking concomitant anti-epileptic therapy which induced or inhibited drug metabolising enzymes, or a combination of both, together with LTG. To survey medical staff who use a routine LTG assay service with a view to establishing the utility of higher plasma LTG concentrations than those used in early clinical trials. Methods All patient assays for LTG received over a 12 month period (339 requests from 149 patients) were reviewed and relationships between dosage and concentration calculated and grouped according to concomitant antiepileptic drug therapy. The doctors requesting the tests were surveyed by questionnaire (n=40 of 67 responded). They were asked for details about the patient's seizure control, rationale used for LTG dosage adjustment and their acceptance of the proposed 'therapeutic range' adopted by the laboratory of 3-14 mg l −1 . Results Linear relationships were demonstrated between LTG dosage and concentration for the 3 treatment groups (LTG plus valproic acid (VPA), LTG plus enzyme inducing antiepileptic drugs, and LTG plus VPA and inducers), however, there were significant differences between groups ( P<0.001) with a 4.4 fold difference in dosage5concentration ratios between the LTG plus VPA group and the LTG plus inducers group. The questionnaire showed that the therapeutic range was well accepted by 88% of responders, none of whom considered this higher range to be wrong. Conclusions Metabolic inhibition by VPA was shown to have a marked effect on LTG kinetics, suggesting either a significant LTG dosage reduction is required if plasma LTG concentrations are elevated, or alternatively, higher plasma LTG concentrations could be attained from lower dosages. The higher therapeutic range adopted by the laboratory (3-14 mg l −1 ) was widely accepted and increasingly applied in clinical practice in the management of patients with epilepsy. and 10%, respectively) and other minor N-oxide metabolites,
Introduction secondary generalisation, as well as generalised tonic-clonic seizures and other generalised seizures (e.g., absence, Lamotrigine (LamictalA, Glaxo-Wellcome, BW430C, 3,5-diamino-6(2,3-dichlorophenyl)-1,2,4-triazine) is one of myoclonic, tonic); it also has beneficial mood altering properties [5] [6] [7] [8] . CNS side-effects are less marked than with the newer antiepileptic drugs (AED) and is currently marketed in Australia as 'add-on' therapy to other AEDs. either phenytoin (PHT) or carbamazepine (CBZ) [9, 10] . The kinetics of LTG are linear over the established plasma However, it is being widely used internationally as monotherapy [1] . It acts by inhibiting pre-synaptic voltage-concentration range. It has bioavailability close to 100% after oral dosing, and protein binding of~50%. Its clearance sensitive sodium channels and excitatory neurotransmitter release ( principally glutamate) and inhibits repetitive firing (and hence terminal half-life) is affected by the presence or absence of concomitant enzyme inducers or inhibitors. With of action potentials characteristic of epileptic foci [2] [3] [4] . Its broad range of activity has been demonstrated in clinical enzyme inhibition by valproic acid (VPA) the half-life increases from approximately 24 h to as much as 60 h, trials, including placebo controlled, cross-over design, concentration controlled trials. It has been shown to have whereas with inducers (PHT, CBZ, phenobarbitone (PHB)) it is reduced to approximately 15 h [11] [12] [13] [14] . LTG is metabolised hepatically to N-2-and N-5-glucuronides (80% 70% of which are recovered in urine [15] . It has mild auto-groups are detailed in Table 1 . The plasma LTG concentration and dosage, as well as other AED therapy were induction of metabolism with chronic therapy [16] .
A 'therapeutic range' for LTG is not well established or recorded. There was no LTG monotherapy group given the current regulatory status for this drug in Australia as 'add-accepted as early clinical trials targeted plasma concentrations of 1-3 or 1-4 mg l −1 which did not appear to correlate on' therapy. The ratio of daily dose (mg day −1 ) to plasma LTG concentration (mg l −1 ) was calculated. The requesting well with pharmacological effects [17] [18] [19] [20] . Even at these concentrations there have been suggestions that patients doctors (n=67) were sent a questionnaire for completion. In addition to clinical issues (considered elsewhere), questions with LTG concentrations at the upper end of this range may have had better responses [21] . However, later studies asked included: $ detail about dosage of LTG and concomitant therapy suggested that these concentrations may have been too low, and showed that some patients tolerated concentrations $ factors affecting selection of LTG dosage (including seizure frequency, toxicity, dosage recommendations-above 10 mg l −1 with additional 'benefits and without clinical toxicity' [22] . In a more recently published open commercial or regulatory authorities, assay result and therapeutic range reported, experience with other patients trial with LTG and vigabatrin (VGB), 40% of patients with 'intractable epilepsy' had seizure reductions of 80-100%, on LTG, feed-back from patient), $ the usefulness and appropriateness of the 'therapeutic and mean trough LTG concentrations were 9.9 mg l −1 (range 3.4 to 19.6 mg l −1 ). The median plasma LTG range' provided with results. Doctors were asked to select from 'wrong', 'unhelpful', 'helpful' or 'very helpful'. concentration at which the monthly seizure frequency fell by at least 50% was 7.9 mg l −1 (range 2.1-15.4 mg l −1 ), Where possible, rating scales were used (allowing ticking of boxes) to facilitate completion of questions and data and the median concentration at which dose-related sideeffects (including ataxia, diplopia, dysarthria, headache collation. The extension study to the above review was undertaken and vomiting) appeared was 16.0 mg l −1 (range 7.9-19.4 mg l −1 ) [6] . These authors suggested that the LTG to determine the range of LTG concentrations measured in 150 consecutive specimens during the initial 12 month 'therapeutic range is significantly higher than that previously proposed (1.5-3 mg l −1 )'. period of the service and a further 150 assayed more recently (being 2 years after introducing the service) to consider the A routine assay for LTG was established in our laboratory in late 1995 and a therapeutic range of 3-14 mg l −1 distribution of LTG concentrations across the 'therapeutic range' and whether there were any shifts in the concen-adopted, based on the observations in the above study [6] and further clinical experiences of one of our group (ABB) trations used clinically over this period. LTG concentrations were determined by a specific It should be noted that an h.p.l.c. assay for LTG was available locally prior to our service, but the other laboratory h.p.l.c./u.v. technique which has been described [23].
Essentially it involves extraction of the basified plasma continued to recognize the 1 to 3 mg l −1 range. Prior to introducing our service, successful correlation studies were fraction into ethyl acetate, which is separated, dried and reconstituted in acetonitrile. Chromatographic separation undertaken with this other laboratory.
We present a retrospective review of the acceptance and was performed on a silica column with methanol/water/ phospate buffer mobile-phase at detected by u.v. absorption utilisation of this LTG assay service, undertaken 12 months after it was introduced, by surveying all the medical staff at 280nm. The methods had within-and between-run CVs of less than 8% and performance managed through internal who had requested LTG tests during this period. A particular focus of the questionnaire used was the utility and acceptance bi-level quality control samples assayed in parallel, and externally through an international quality assurance program of the higher 'therapeutic range' quoted. These doctors were also asked about the emphasis they placed on a variety (HeathControl, Cardiff, Wales) where proficiency has proved consistently acceptable. of factors influencing LTG dosage selection for their patients. In a subsequent study, we compared the distribution of 150 unselected consecutive LTG concentrations measured Results in our laboratory during this 12 month period, with an equivalent 150 over the following 12 months, to consider
The range of LTG concentrations measured (shown in Figure 1 ) were, not surprisingly, highly variable but with an whether there was a trend toward adopting higher LTG concentrations.
approximately two-fold higher mean LTG concentration in patients also taking VPA (n=74) than those prescribed inducer(s) (CBZ and/or PHT), (n=91). Those on com-Methods binations of LTG with VPA and inducer(s) (n=89) had intermediate mean concentrations. However, when All assays performed by this laboratory over a 12 month period (October 1995 to 1996) were included in the study.
expressed as LTG dose to concentration ratios (shown in Figure 2 ), patients on inducer(s) had on average a 4.4 fold This included 339 specimens drawn >6 h post-dose from 149 patients. Data were divided into three groups according greater LTG dose5concentration ratio than those prescribed VPA without inducer(s), reflecting induction and inhibition to the other AED therapy each patient was prescribed. These groups were; (1) patients taking LTG plus VPA, (2) respectively of LTG metabolism. Patients taking a combination of VPA and inducers with LTG had intermediate LTG plus both VPA and inducers and (3) LTG plus enzyme inducers (CBZ and/or PHT, there being none taking PHB).
LTG dose5concentration ratios. The relationships between LTG dosage (mg day −1 ) and The mean (±s.d.), median, mode, minimum and maximum dosages of each drug for patients studied in these three plasma LTG concentrations (mg l −1 ), (using repeated Responses to the questionnaire were received from 40 in Table 2 . This shows that seizure frequency and adverse side- ) reported with the LTG assay result rated as important with 73% of doctors but clearly less than either seizure frequency or toxicity. Experiences with other patients taking LTG compared closely in importance to the therapeutic range. The use of other AEDs rated quite highly in importance, as did feedback from patients, both rating more than therapeutic range or experience with other patients on LTG, but less than seizure frequency or toxicity. Hence the lowest rating was given to recommended dosage guidelines (including those of the manufacturer, national publications, etc).
In response to the specific question about the utility of the therapeutic range adopted by this laboratory (3 to 14 mg l −1 ), none of the doctors surveyed thought the range was 'wrong' and 88% found it to be 'helpful' or 'very helpful'. The more recent review of the frequency distribution of reflecting a marked usage (34% of the total) of LTG concentrations in the 1-3 mg l −1 range, where as at 2 years (ie., a further 12 months after the survey) there was a 27% reduction in concentrations within this range, accompanied measures ANOVA) were linear for the three treatment groups, and were significantly different between groups by 35% and 22% increases in the 3-5 and 5-7 mg l −1 categories, respectively. ( P<0.001), as follows: Seizure frequency  70  21  6  3  0  0  Adverse effects  55  33  9  3  0  0  Dosage guidelines  3  25  28  25  16  3  Therapeutic range  6  46  21  12  12  3  Other patient experience  7  43  23  13  13  0  Use of other AEDs  16  44  22  16  3  0  Patient's feedback  26  52  16  7  0  0 24-27]. The dose5concentration ratio (mg day −1 5mg l −1 ) difference of 4.4 fold between LTG plus VPA, and LTG plus inducer(s) is comparable with data recently reported [28] where patients on LTG and VPA had a concentration5dose ratio (mg l −1 5mg kg −1 day −1 ) of 3.4±2.0 compared with 0.6±2.0 for those on LTG and enzymes inducers. However, it must be observed that, while the dose5concentration ratio is very different in the three groups, there is considerable overlap, and lower LTG concentrations in patients on inducers and higher concentrations in patients on VPA, cannot be assumed without resort to assay. LTG concentrations can be expected to rise following withdrawal from enzyme inducing AEDs. Many patients experience their best seizure control at this stage and may become seizure-free for the first time (ABB personal observation). In addition, a marked dosage reduction may be required if VPA is to be introduced to a patient's therapy. Alternatively, the addition of VPA may be a convenient means of increasing 'low' plasma LTG concentrations 1-2.9 3-4.9 5-6.9 7-8.9 9-10.9 11-12.9 13-14.9 15-16.9 >17 without requiring an increase in LTG dosage and the added rin, by agents such as diltiazem [29] . The major difference
Rating scale responses(%) Very important CCCCCCCCCCCCCA Not important
The laboratory quotes a 'therapeutic range' of 3-14 mg l −1 with in the usage of VPA as the 'sparing agent' with LTG is that all reports issued.
VPA is indicated for the same clinical condition, i.e., epilepsy, and so has fewer ethical issues in relation to its use Discussion for an 'economic' purpose. The survey of doctors requesting LTG assays showed that The value of plasma LTG concentration monitoring has proved to be controversial as it has been suggested that there seizure frequency and adverse effects rated the most important factors in establishing LTG dosage, that many is a poor relationship between concentrations and pharmacological responses (either efficacious or toxic) [18] [19] [20] . As the were not 'constrained' by published dosage guidelines, and that they did use the quoted therapeutic range as a guide. plasma LTG concentrations used in clinical trials were typically in the 1 to 3 mg l −1 range, the possibility exists Taking these factors together, it is likely that if toxicity had proved to be dose limiting in their patients, they would not that these concentrations were too low and hence a relationship with pharmacological effects could not be have increased the LTG dosage just to attain the advertised 'therapeutic range' reported by the laboratory. The fact that demonstrated.
As noted above, clinical studies [6] showed the median 88% of these same doctors then indicated that this higher therapeutic range was 'helpful' or 'very helpful' and none plasma LTG concentration at which there was a 50% reduction in the monthly seizure frequency was 7.9 mg l −1 thought it to be 'wrong', suggests that we are providing a valuable guide to LTG therapy and not exposing patients to (range 2.1-15.4 mg l −1 ), and the median concentration at which dose-related side-effects appeared was 16.0 mg l −1 undue risk. This was further supported by the increasing trend shown (independent of the questionnaire) for a larger (range 7.9-19.4 mg l −1 ). Based on these data and further clinical experience suggesting the need to increase LTG proportion of patients having LTG concentrations above 3 mg l −1 in the second 12 month period. dosage and concentration to achieve optimal response, we presented a higher concentration range at the time of A qualification of our study is that we surveyed doctors selected on the basis of assay requests received by our introducing the LTG assay service in our laboratory.
The dramatic effect of enzyme inhibition (by VPA) or laboratory. Hence we may have only surveyed those committed to the use of LTG assays, excluding those who induction (by CBZ and/or PHT) is well established [13; 
